Li H, Ye B
Synth Syst Biotechnol. 2024; 10(1):226-236.
PMID: 39582690
PMC: 11585803.
DOI: 10.1016/j.synbio.2024.09.001.
Xie H, Li L, Guo Y, Zhou L, Ma L, He A
Heliyon. 2024; 10(18):e37512.
PMID: 39315215
PMC: 11417555.
DOI: 10.1016/j.heliyon.2024.e37512.
Oghalaie A, Hosseini M, Hosseininejad-Chafi M, Eftekhari Z, Behdani M, Kazemi-Lomedasht F
Med Oncol. 2024; 41(10):239.
PMID: 39230639
DOI: 10.1007/s12032-024-02478-3.
Takahashi-Nakaguchi A, Horiuchi Y, Yamamoto M, Totsuka Y, Wakabayashi K
Toxins (Basel). 2024; 16(6).
PMID: 38922164
PMC: 11209040.
DOI: 10.3390/toxins16060270.
di Leandro L, Colasante M, Pitari G, Ippoliti R
Toxins (Basel). 2023; 15(12).
PMID: 38133203
PMC: 10748335.
DOI: 10.3390/toxins15120699.
Novel Anti-Mesothelin Nanobodies and Recombinant Immunotoxins with Exotoxin Catalytic Domain for Cancer Therapeutics.
Nguyen M, Kim D, Shim H, Ta H, Vu T, Nguyen T
Mol Cells. 2023; 46(12):764-777.
PMID: 38052492
PMC: 10701305.
DOI: 10.14348/molcells.2023.0155.
A pH-Responsive Virus-Like Particle as a Protein Cage for a Targeted Delivery.
Kim K, Kim G, Bae J, Song J, Kim H
Adv Healthc Mater. 2023; 13(4):e2302656.
PMID: 37966427
PMC: 11469083.
DOI: 10.1002/adhm.202302656.
Potent and selective eradication of tumor cells by an EpCAM-targeted Ras-degrading enzyme.
Palacio-Castaneda V, van de Crommert B, Verploegen E, Overeem M, van Oostrum J, Verdurmen W
Mol Ther Oncolytics. 2023; 30:16-26.
PMID: 37485031
PMC: 10362089.
DOI: 10.1016/j.omto.2023.06.002.
Lipid nanoparticles-loaded with toxin mRNA represents a new strategy for the treatment of solid tumors.
Granot-Matok Y, Ezra A, Ramishetti S, Sharma P, Somu Naidu G, Benhar I
Theranostics. 2023; 13(11):3497-3508.
PMID: 37441597
PMC: 10334842.
DOI: 10.7150/thno.82228.
Targeted Anticancer Agent with Original Mode of Action Prepared by Supramolecular Assembly of Antibody Oligonucleotide Conjugates and Cationic Nanoparticles.
Lehot V, Neuberg P, Ripoll M, Daubeuf F, Erb S, Dovgan I
Pharmaceutics. 2023; 15(6).
PMID: 37376091
PMC: 10305667.
DOI: 10.3390/pharmaceutics15061643.
Design and construction of scFv-PE35KDEL as a novel immunotoxin against human epidermal growth factor receptor 2 for cancer therapy.
Shariaty Vaziri Z, Shafiee F, Akbari V
Biotechnol Lett. 2023; 45(4):537-550.
PMID: 36807722
DOI: 10.1007/s10529-023-03360-4.
Synergistic Effect of the Combined Action of Targeted and Photodynamic Therapy on HER2-Positive Breast Cancer.
Balalaeva I, Krylova L, Karpova M, Shulga A, Konovalova E, Guryev E
Dokl Biochem Biophys. 2023; 507(1):330-333.
PMID: 36786996
DOI: 10.1134/S1607672922340038.
Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin-Toxin Fusion in a Pancreatic Cancer Xenograft Model.
Xu T, Schulga A, Konovalova E, Rinne S, Zhang H, Vorontsova O
Int J Mol Sci. 2023; 24(3).
PMID: 36769161
PMC: 9917732.
DOI: 10.3390/ijms24032838.
Targeting the Inside of Cells with Biologicals: Toxin Routes in a Therapeutic Context.
Ruschig M, Marschall A
BioDrugs. 2023; 37(2):181-203.
PMID: 36729328
PMC: 9893211.
DOI: 10.1007/s40259-023-00580-y.
Modification of bacterial cells for remotely guided systems.
Rybkin I, Pinyaev S, Sindeeva O, German S, Koblar M, Pyataev N
Front Bioeng Biotechnol. 2023; 10:1070851.
PMID: 36686260
PMC: 9845715.
DOI: 10.3389/fbioe.2022.1070851.
Synthesis of an Anti-CD7 Recombinant Immunotoxin Based on PE24 in CHO and Cell-Free Systems.
Krebs S, Stech M, Jorde F, Rakotoarinoro N, Ramm F, Marinoff S
Int J Mol Sci. 2022; 23(22).
PMID: 36430170
PMC: 9697001.
DOI: 10.3390/ijms232213697.
Do Bacteria Provide an Alternative to Cancer Treatment and What Role Does Lactic Acid Bacteria Play?.
Dicks L, Vermeulen W
Microorganisms. 2022; 10(9).
PMID: 36144335
PMC: 9501580.
DOI: 10.3390/microorganisms10091733.
Strategies to mitigate the on- and off-target toxicities of recombinant immunotoxins: an antibody engineering perspective.
Li M, Mei S, Yang Y, Shen Y, Chen L
Antib Ther. 2022; 5(3):164-176.
PMID: 35928456
PMC: 9344849.
DOI: 10.1093/abt/tbac014.
in Cancer Therapy: Current Knowledge, Challenges and Future Perspectives.
Pang Z, Gu M, Tang T
Front Oncol. 2022; 12:891187.
PMID: 35574361
PMC: 9095937.
DOI: 10.3389/fonc.2022.891187.
GSDMD-dependent pyroptotic induction by a multivalent CXCR4-targeted nanotoxin blocks colorectal cancer metastases.
Sala R, Rioja-Blanco E, Serna N, Sanchez-Garcia L, Alamo P, Alba-Castellon L
Drug Deliv. 2022; 29(1):1384-1397.
PMID: 35532120
PMC: 9090371.
DOI: 10.1080/10717544.2022.2069302.